Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy discusses recently developed treatments based on molecular targets which are genetically altered in cancer cells and are essential for tumor development and survival. Considerable research effort has been devoted to the development of targeted drugs that inhibit the action of pathogenic kinases, and clinical studies performed so far have validated the positive effects of kinase inhibitors for cancer treatment. Each chapter discusses a molecular target, such as ALK2, ATR, CK, Src-Abl, EGFR, Fyn-Blk-Lyn, IGFs, and PAK1.
The book's chapters are written by experts who actively work on the targets to help readers fully understand how they can be used. This is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of novel cancer therapies based on molecular targets.
1. Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy - p. i 2. Cover - p. i 3. Title Page - p. ii 4. Copyright Page - p. iii 5. Table of Content - p. iii 6. Dedication - p. v 7. Contributors - p. xi 8. Preface - p. xiii 9. Acknowledgments - p. xv 10. Chapter 1 Activin receptor-like kinase-2 inhibitors - p. 1 11. Chapter 2 Ataxia telangiectasia and Rad3-related protein inhibitors - p. 17 12. Chapter 3 Breakpoint cluster region Abelson kinase inhibitors - p. 37 13. Chapter 4 Casein kinase (CK) inhibitors - p. 45 14. Chapter 5 Recent updates on c-Src kinase and Src-Abl nonreceptor tyrosine kinases inhibitors - p. 83 15. Chapter 6 Cyclin-dependent kinase 4 and 6 in cancer: Exploration of CDK4/6 inhibitors as anticancer agents - p. 115 16. Chapter 7 Impact of epidermal growth factor receptors as a key clinical target against cancer - p. 139 17. Chapter 8 Cancer and insulin-like growth factor inhibitors: Recent advancements and SAR analysis - p. 161 18. Chapter 9 Mitotic kinesin spindle protein (KSP/Eg5 ATPase) inhibitors - p. 183 19. Chapter 10 p21-Activated kinase 1 inhibitors - p. 201 20. Chapter 11 p38 mitogen-activated protein kinase inhibitors - p. 219 21. Chapter 12 Proviral integration site for Moloney murine leukemia virus-1 (PIM-1) kinase inhibitors - p. 255 22. Chapter 13 Rearranged during transfection (RET) inhibitors - p. 323 23. Chapter 14 Serine/threonine-protein kinase B-Raf inhibitors - p. 377 24. Chapter 15 Tubulin polymerization inhibitors - p. 395 25. Chapter 16 Tumor necrosis factor receptor–associated protein 1 (TRAP1) inhibitors - p. 419 26. Chapter 17 Vascular endothelial growth factor receptors (VEGFR/PDGFR) inhibitors - p. 443 27. Index - p. 477
Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy discusses recently developed treatments based on molecular targets which are genetically altered in cancer cells and are essential for tumor development and survival. Considerable research effort has been devoted to the development of targeted drugs that inhibit the action of pathogenic kinases, and clinical studies performed so far have validated the positive effects of kinase inhibitors for cancer treatment. Each chapter discusses a molecular target, such as ALK2, ATR, CK, Src-Abl, EGFR, Fyn-Blk-Lyn, IGFs, and PAK1.
The book's chapters are written by experts who actively work on the targets to help readers fully understand how they can be used. This is a valuable resource for cancer researchers, oncologists, graduate students and members of the biomedical field who are interested in the potential of novel cancer therapies based on molecular targets.
1. Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy - p. i 2. Cover - p. i 3. Title Page - p. ii 4. Copyright Page - p. iii 5. Table of Content - p. iii 6. Dedication - p. v 7. Contributors - p. xi 8. Preface - p. xiii 9. Acknowledgments - p. xv 10. Chapter 1 Activin receptor-like kinase-2 inhibitors - p. 1 11. Chapter 2 Ataxia telangiectasia and Rad3-related protein inhibitors - p. 17 12. Chapter 3 Breakpoint cluster region Abelson kinase inhibitors - p. 37 13. Chapter 4 Casein kinase (CK) inhibitors - p. 45 14. Chapter 5 Recent updates on c-Src kinase and Src-Abl nonreceptor tyrosine kinases inhibitors - p. 83 15. Chapter 6 Cyclin-dependent kinase 4 and 6 in cancer: Exploration of CDK4/6 inhibitors as anticancer agents - p. 115 16. Chapter 7 Impact of epidermal growth factor receptors as a key clinical target against cancer - p. 139 17. Chapter 8 Cancer and insulin-like growth factor inhibitors: Recent advancements and SAR analysis - p. 161 18. Chapter 9 Mitotic kinesin spindle protein (KSP/Eg5 ATPase) inhibitors - p. 183 19. Chapter 10 p21-Activated kinase 1 inhibitors - p. 201 20. Chapter 11 p38 mitogen-activated protein kinase inhibitors - p. 219 21. Chapter 12 Proviral integration site for Moloney murine leukemia virus-1 (PIM-1) kinase inhibitors - p. 255 22. Chapter 13 Rearranged during transfection (RET) inhibitors - p. 323 23. Chapter 14 Serine/threonine-protein kinase B-Raf inhibitors - p. 377 24. Chapter 15 Tubulin polymerization inhibitors - p. 395 25. Chapter 16 Tumor necrosis factor receptor–associated protein 1 (TRAP1) inhibitors - p. 419 26. Chapter 17 Vascular endothelial growth factor receptors (VEGFR/PDGFR) inhibitors - p. 443 27. Index - p. 477
